All right. Good morning, everyone. Thank you to everyone who is here in the room on the first morning of the Jefferies London Healthcare Conference. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today Dr. Mark Goldsmith at RevMed. Mark has warned me that a lot of the questions that I have prepared, he may or may not be able to answer, but I will certainly try. Mark, could you kick us off with just a brief introduction, and then we will get into some questions that you may or may not answer?
Thanks very much for having us here today. Revolution Medicines is a company focused intensively on RAS-addicted cancers, RAS being the most common oncogene in human cancers. We have developed a very deep pipeline of RAS-focused compounds, inhibitors, many of which are in the clinic now, many of which are showing great promise. The most prominent one, of course, is now called RASONQUE, a commercial-stage compound just approved by the FDA late this summer, and now pending elsewhere around the world. We are completely committed to trying to defeat these RAS-addicted cancers, and our current therapies are making a difference, and we will continue investing to try to do even better.
Got it. Awesome, Mark. You just reported your first quarter of sales. Actually, it was not even a quarter, it was five weeks of sales. Can you just kind of recap for us what you saw in those first few weeks of your first reporting period? There were a number of investor questions about how to think about this going forward, but before we get into that a little bit, can I just get your perspective?
Right. We reported on five weeks of sales. Of course, that is a very short period of time. We did report net sales of $198 million during that period. There are many contributors to that, and I think our commercialization folks talked about that a bit on the call. There were several different categories of patients who received prescriptions during that period of time. Some of those patients came off of our Expanded Access Program and converted or transitioned over to commercial drug. It was a very healthy Expanded Access Program, one of the fastest programs with great uptake. There were greater than 2,000 patients in that program, and many of those patients did transition over to commercial drug. That would be essentially a one-time contributor. Those patients transitioned over and will take commercial drug as long as it is beneficial to them.
A second category in that group were patients who had not participated in the Expanded Access Program in the U.S. but were waiting for drug, and many of those patients were late stage. Some of those patients were even on hospice care, and once the drug was available, were given an opportunity to take something that was highly differentiated from the options that they had already used up. That too is probably a roughly one-time population as more and more patients of the third group come online, and those are patients with previously treated disease but who have not advanced to third or fourth line, so-called second-line patients. That's really the core population that we studied in the RASolute 302 trial. The results were quite distinctive with the substantial hazard ratios and overall survival, progression-free survival, breaking the one-year barrier. Very much attracting attention by those second-line patients.
That third group will really ultimately form the core of the stable population that will enter treatment with RASONQUE as those first two groups work their way through the system. That first five-week period is a complicated period. We didn't break down the details of who those patients were, largely because there aren't patterns that are easily recognizable at this point in time. There's just too much variability. As things begin to stabilize, we'll of course provide more information. As we get into a more stable growth pattern, we'll share that information.
Yeah, Mark, the reason why this was. Obviously, investors don't like uncertainty, so your inability to kind of be able to parse out these three separate groups was just like a matter of discussion. I guess on a forward-looking basis, once you guys report fourth-quarter earnings, I guess two questions with that, right? Do you expect to be able to pre-announce your fourth-quarter revenues in January? Then also, at that point in time, whether it's in January or in February with proper 10-K filing period, would you expect to be able to give some clarity on how to think about the kind of one-off groups compared to your sort of regular way of demand?
Yeah. Well, we don't like uncertainty either, and the uncertainty is actually baked into the data. It's not a question of whether we disclose the data, that the uncertainty would remain with them, and that's just the nature of a launch that has had such a steep trajectory but also had substantial complexity in it because of the Expanded Access Program. I can't comment today on when we'll first disclose the fourth-quarter results. We know there's a lot of interest in having those results. We have interest in having those results, and we don't have them yet. But we'll see when it's possible to disclose that. I think it's fair to say that over time, we'll get more granular about the various things that you're asking about, but I can't commit today to whether that's in the next quarter or in two quarters.
I think what we're going to do is to try to see patterns in the data. When things look like they are stable enough that one can use it as substantive information to project the future, that's when we'll be able to share it.
Got it. Can you just speak a little bit about what you guys have done to ensure kind of seamless execution and commercial availability? Something that really stood out to me was on the earnings call, you used the word responsibility and delivery to refer to kind of the mission that's ahead to kind of get this to patients. Can you just talk about what you've done to be prepared and what investments you've made to make sure this gets to patients?
Yeah. For many years now, we've had the concept that we would start as a discovery company, we'd move on to development, then we'd move on to delivery. Now we're in that delivery chapter. I think with the results that we reported on RASolute 302, we do have a great responsibility to physicians and patients, and we take that very seriously throughout the company. We, of course, had no commercial capability as a company two or three years ago. We anticipated the success of RASONQUE, at least on some level, and began investing in building commercial capability. We managed to recruit a very high talent group of individuals from established entities, well-known entities, that joined us and really had a blank slate.
They anticipated the possibility that we'd have an important medicines on our hand, one or more, and set out to build the relationships across the country. We had our medical affairs organization out for really the last two years, building relationships with investigators and with community docs. We spent a lot of time understanding RASONQUE itself. We had patient-reported outcomes as part of the trial. Every trial does have patient-reported outcomes, but this was a relatively unique case in which the patient-reported outcomes were statistically nearly identical to those of the objective data, indicating that patients felt that their experience of the drug matched what we were seeing objectively. That's very important information for doctors to have to be able to share with patients. There's also a side effect profile associated with RASONQUE, and we knew that. We saw that emerge.
We developed approaches to mitigate when those side effects occur, and even more importantly, to pre-treat to try to reduce the incidence or severity of those side effects. We developed a very straightforward system for educating physicians about that, and that is working well, and it is part of the process of establishing that this drug should be used more broadly. We also set up the (ON)Path Patient Services Program at RevMed, which is a dedicated group of professionals who respond very quickly to inquiries by physicians or patients about a whole range of topics, but now they are very focused, obviously, on third-party coverage. They facilitate if a patient has trouble getting coverage, they can step in, help to fill out prior auths, take care of that sort of thing while we are in the exception period, since most payers do not yet have established RASONQUE in their pathways.
That just takes a while to do. It is just the mechanics of it. They are not resistant at all to patients receiving it, but the systems are not in place, so we do some handholding of that. Of course, we also provide patient assistance, and our objective is to make sure that every patient who needs access to RASONQUE receives it, regardless of their ability to pay.
Got it. Mark, can I just ask you to sort of double-click on the point around tolerability? You spoke to the exceptional efficacy and quality of life outcomes that you saw in the study. For a couple of reasons, there was a prominent media report, and also, I think part of it is that there is not much else to pick at. Investors have kind of really concerned themselves to some extent with the tolerability profile of RASONQUE. Can you speak about what exactly you are doing to kind of ease any friction in the real world and what kind of results and feedback you are getting from the treating physicians?
Well, we defined the tolerability and safety profile in the phase III trial, and it is actually, although there are common side effects, they are usually quite well managed. In fact, I think only under 2% of patients discontinued RASONQUE for side effects, which is, I think, a phenomenal figure. Most patients continue drug. Some patients take a holiday, a one-week, sometimes two-week holiday from the drug. Sometimes patients have reduction, but two-thirds of patients do not have any reduction. So generally, it is a well-tolerated drug, and very few patients say that they would rather not have RASONQUE. So that is what the 302 trial showed us. We did develop some approaches for pre-treating patients. The experience with cetuximab informed the skin side effects for sure. Pre-treatment does reduce the incidence and severity, and a protocol for how to respond if those side effects occur.
Mucositis or stomatitis can occur, and there are topical ways to deal with that, and sometimes a break in treatment period is required. We don't believe it has any effect on long-term efficacy. Then there's some GI side effects, typically diarrhea, and that can be managed as well. So that's generally how it's played out.
Got it. Okay. So kind of shifting more to the future—
May I just say, though, you said there were some reports about it, and I don't know, you said public reports. Were you alluding to the FAERS report or something like that?
No, we can talk about that if you want.
I'm not talking about it.
No, I was talking about the—
It can be very short. It's total nonsense. They took a database that they didn't understand, and they came to conclusions that didn't mean anything. There's nothing We're not aware of any public reports of any substance that would affect how people perceive it.
Got it. Okay. Yeah, no, I was referring to the Ben Sasse interview where I think people saw that, and I think from the investment community, we're used to looking at things on paper and spreadsheets. I don't think people appreciated what a grade three rash actually looks like, so that's what I was referring to.
Yeah, I can't, of course, speak specifically to any patient's individual case. There are rare cases of individuals who will have a severe skin side effect like that. I can't really even comment on whether that senator was even taking RASONQUE. But, we have seen some cases of that. They're uncommon. Typically, that means that somebody didn't deal with it early on when the rash started to occur and continued to treat at the same dose and without any break. Sun exposure also substantially contributes to it. Again, we found, based on the objective data from the 302 study and everything we've heard from physicians, so far today, that it's very uncommon for somebody to desire to discontinue RASONQUE.
Got it. I want to shift gears to talking about the future. In frontline pancreatic cancer, that's where you're going next. You're kind of blanketing the landscape, right? Within your phase III development program, you have daraxonrasib, both alone, combined with chemo. You have your G12D inhibitor combined with chemo, also combined with daraxonrasib. And there will be phase III trials starting with PRMT5 inhibition. What is your vision for frontline pancreatic cancer?
Well, it's really important to find good solutions in frontline pancreatic cancer because that's where we can really impact the overall life experience for somebody who's living with pancreatic cancer. It's a high priority. We take a bit of a humble approach to it in that we don't really know today, can't predict which of these strategies is most likely to be effective, and we also recognize that patients are diverse, and so different patients may prefer different approaches or have particular needs that one approach or another can't address. We've decided that we will unlock any compelling strategy in first line. We have the resources to do it, we have the financial capability, the development capability, and we'll evaluate it, and we'll let those sort of chips fall where they may. We, of course, also now have created a cottage industry of competitors.
We've informed everybody how to go about developing RAS inhibitors, and so there are lots of folks who are trying to find ways to pick off a piece of that action. We have to compete with all of those, and the best way we can do that is to figure out the most compelling, scientifically driven, and compelling strategies. Each of those strategies that we're testing is associated with a different hypothesis. There's a different reason why we think each of those might end up being useful, but it's very hard to predict how they'll play against each other. We'll just play them all out and let the chips fall where they may.
Got it. Mark, I heard something really interesting. I was at ESMO a few weeks ago, and some of the physicians were telling me that they really see daraxonrasib as a backbone, where you can start with daraxonrasib. I guess it still takes a few weeks to get NGS testing results, and the docs were saying, "Well, we'll start darax, we'll wait for the results. If it's G12D, we can add zoldonrasib. If it's MTAP deletion, we can add a PRMT5. If neither, we can think about adding chemo." I thought that was a really interesting perspective. Is that how you see the world? Does that make sense to you?
It's true that unlike lung cancer, where 85% of patients now know their mutational status, their genotype for their tumor, given 20 years of experience of doctors learning to make that part of their routine, that's not true in pancreatic cancer. Most patients don't actually know their tumor genotype, or if it's known, it's in a PDF file that's stuck in the back of a chart that nobody can see. So it's just not yet been institutionalized. Furthermore, more than 90% of pancreatic cancers are caused by a RAS mutation, and even those that aren't caused by a RAS mutation are probably still caused by RAS signaling. So it's a situation where a RAS(ON) multi-selective inhibitor makes the most sense to use to introduce immediately. We do imagine that RASONQUE will become a backbone for treatment.
There are a variety of things that could be added to it. We've already done some of those experiments, at least in early phase I, II trials, and now with a number of phase III trials. Adding another RAS inhibitor can double down on RAS inhibition, give you more effective inhibition of the RAS pathway. In MTAP-deleted tumors, adding a PRMT5 inhibitor can create synthetic lethality that clearly is additive to RASONQUE. Even starting with chemotherapy plus RASONQUE can be highly active, and we've shown that previously in an early study. We'll be providing an update on the RASONQUE plus GnP combination in first-line pancreatic cancer at the Triple Meeting, actually this week, later this week. That will continue to mature, and we're running phase III trials. So each of these is a different hypothesis.
They're worth testing, and if RASONQUE becomes the standard of care, as it looks like it has the opportunity to do, then people will be looking to build their treatment regimens on top of that. Would also say that we're very interested not just in what's the first activity that a patient experiences, but how do you sustain that? I think sustaining durability of response and being able to deal with it once somebody does progress, since most of these patients are not being cured at this stage, what comes next? I think what you just talked about is also a core part of the strategy, which would be keep the foot on the brake of the RAS signaling, don't let that up, but add something else that addresses what the resistance mechanism is.
And we have a pretty good idea of what those resistance mechanisms are from deep studies that we've done in patients as well as preclinical work, but largely in patients. A lot of it is actually RAS signaling. The first thing a tumor does to overcome a RAS inhibitor is to turn the volume up on RAS. So finding another way to come back and knock that back down is going to be important. But there can be other non-RAS contributors, and we know that those sorts of things can be added, inhibitors of those other pathways can be added. So it will be very interesting to see how this plays out over time. We do not know exactly, but we have got the tools and we will let it play.
Got it. So Mark, you mentioned Triple Meeting coming up later this week. So one of your competitors in the multi-RAS space will have an update on their phase I study. Can I just ask you to comment on how you are seeing the competitive landscape, other companies that are trying to have kind of me-too or me-better approaches to daraxonrasib?
Yeah, we see lots of companies trying to do that. I cannot really comment on their data because we have not seen the data. Generally speaking, as I said, we have enabled a lot of it. I know one such company says they watch everything we do and then they start the next week to try to reproduce it in their own way. That is fine. That is normal to happen. I think we are more interested in the innovative strategies, not so much the me-toos. I think RASONQUE sets a pretty high standard, and for somebody to beat it is going to be tough, but more power to them if they can. Internally, our guidance to our science organization is that if anybody can beat us, it should be us.
We should understand the limitations of our compounds, understand what is happening in the biology, and be able to come up with the solutions to that, and we are deeply focused on doing that. And in fact, we will be introducing our fifth RAS(ON) inhibitor into the clinic this quarter. It is the leading member of a new class of innovative inhibitors that is specifically designed to overcome RAS-mediated resistance in tumors that have been treated with a RAS inhibitor but have progressed through RAS resistance. And so that is the first fruit of that investment that we have made, and we will continue investing like that.
Got it. Mark, I think it's awesome that you mentioned RM-055, because personally, I think that's something that investors don't talk about enough or give you enough credit for. In terms of your leadership in the RAS space, given everything you've done with daraxonrasib, does that enable you to move RM-055 faster, and should we expect to see data next year?
Yeah. We've now treated literally thousands of patients with RASONQUE and thousands of patients with other compounds in our pipeline, so we do have a vast clinical experience. Our mantra within the company is to use that as part of a virtuous cycle, learn from it, and do something different next time as a result of that. Certainly, speed is one element of that. I think you'll see some of our compounds move much more swiftly to late-stage development. In the beginning, with RASONQUE, people might remember when daraxonrasib was first described, it was said by many in the field that it was dead on arrival, the compound would never treat anybody's tumor, it would kill patients, it would do all sorts of things.
Oh, it was too large. It broke the rules.
Yeah. It wouldn't be orally bioavailable. It's sort of a very improbable molecule from that perspective. We now have, as I said, thousands of patients' worth of data that tell us otherwise and that have informed how we improve on it. Speed, for sure, matters now, and it matters for patients. I mean, if you're a patient and you're waiting for the next generation, you don't have that much time.
Got it. Do we see data next year?
You'll see some data next year. Something particular?
Oh, for RM-055.
Oh, I don't know. We'll see. I mean, we make those decisions in real time. We look for, what have we learned? Have we learned something important? We are in a different stage as a company. We're in our next chapter, and we have historically been very transparent. That's enabled the field in general to move forward. We're certainly in a commercial stage now, and we're using that information more for our own internal insights and maybe not quite as open about sharing things as rapidly. So you may be disappointed and frustrated at times, but that's just the nature of being able to compete as well.
Got it. We are close to time, but I just wanted to touch on PRMT5 before we let you go.
Yeah.
Tango is saying that they hope to start a phase III study in frontline pancreatic cancer next year with their PRMT5 inhibitor plus daraxonrasib. We have a couple of other PRMT5 collaborations as well. Can you just talk about how you see RevMed's role in kind of either facilitating, enabling, or kind of directly economically partnering with a PRMT5 developer?
Yeah. I mean, I think we have really facilitated the exploration of PRMT5 inhibitors with RAS inhibitors. I mean, that study that Tango has been doing, the phase I, II study, came because we provided RASONQUE to do it, and I think the results are very encouraging. They have achieved clinical proof of concept for the field that has now caused everybody to want to combine their PRMT5 inhibitor with our RAS(ON) inhibitors. We have had actually four collaborations so far, one of which dropped out because they dropped their program. That was Amgen. But we have three others, of which Tango is one. BMS and BeOne also are testing in combination. We think it is a good idea. It should be examined.
As to which of those compounds, whether one, two, or all three should go into phase III trials, I think that is going to be a data-driven decision, and there is nothing from keeping us from supporting all three if that is what makes sense, and we are still evaluating that.
Got it. Okay. Just to kind of leave us off here, as we look towards 2027, you have a number of catalysts coming up. I think you've said you will provide an update on your early-stage combination development in CRC. We'll expect the RASolve 301, your first phase III results in lung cancer. I guess you will at least have data for RM-055, and your G12V is advancing as well.
Yeah.
Then obviously, you'll get into a few more quarters of the commercial experience. Across these kind of handful of events or catalysts over the next 12- 18 months, what would you highlight to all the investors here as what you see as the kind of single biggest next inflection point? Because you've done a great job building the company to this point. Now the question is like, all right, how do you get this from like a $40 billion company to a $60 billion company? So what would you tell investors to pay attention to?
Well, I think you've just described the answer to your question, which is that we have a very large set of phase III readouts coming over the next 12- 24 months, and another large set of phase III trials that we'll initiate during that period of time. I don't think there's a single readout that's going to be the inflection point. We're trying to establish Revolution Medicines, RASONQUE, and the rest of the pipeline as the main drivers of treatment in RAS-addicted disease. I think we're off to a really good start, but we're going to have to keep our pedal to the metal and continue to try to make a difference.
Awesome. Well, thank you, Mark, so much for being here with us today.
Thanks very much.